Revance Therapeutics, Inc. (RVNC): Curtis Ruegg , EVP, Technical Operations of Revance Therapeutics, Inc. sold 1,000 shares on Apr 11, 2016. The Insider selling transaction was reported by the company on Apr 13, 2016 to the Securities and Exchange Commission. The shares were sold at $19.11 per share for a total value of $19,110.00 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Revance Therapeutics Inc is Initiated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has set the Price Target at $46. The Rating was issued on Mar 23, 2016.
Currently the company Insiders own 36.24% of Revance Therapeutics Inc shares according to the proxy statements.Institutional Investors own 95.69% of Revance Therapeutics Inc shares.During last six month period, the net percent change held by insiders has seen a change of -18.56%.
Shares of Revance Therapeutics Inc (RVNC) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.01 points or -0.05% at $19.06 with 2,44,169 shares getting traded. Post opening the session at $19.11, the shares hit an intraday low of $18.9 and an intraday high of $19.53 and the price vacillated in this range throughout the day. The company has a market cap of $542 M and the number of outstanding shares has been calculated to be 2,84,33,208 shares. The 52-week high of Revance Therapeutics Inc is $42.41 and the 52-week low is $15.63.
Revance Therapeutics Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow’s feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications such as glabellar (frown) lines and therapeutic uses such as muscle movement disorders.